Company: DVAX
Filing Date: 2025-04-17
Form Type: PRRN14A
Source: 0001193125-25-084044
Chunk: 6

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-17
Form: PRRN14A
Chunk 6
---
2, and has 
 purchased shares every quarter through Q4 2024.                                                           |

| • |     | Deep Track Capital regularly met with Company representatives following the release of quarterly financial                                              
 results and at investor conferences. During these meetings, Deep Track Capital repeatedly spoke with the Company about capital allocation and strategy. |

| • |     | Beginning in October 2022, Deep Track Capital engaged in a due diligence review of the Company and its board,                                                                                                                                            
 management, operations, capital allocation, strategy, performance, prospects, and related matters. As a result of this review, Deep Track Capital arrived at the conclusion that the Company was significantly undervalued and represented an attractive 
 investment opportunity.                                                                                                                                                                                                                                  |

| • |     | On May 19, 2023, Deep Track Capital filed a Schedule 13G, reporting beneficial ownership of approximately 
 6,556,180 shares of common stock, representing 5.10% of the Company’s outstanding common stock.           |

| • |     | On September 16, 2024, Deep Track Capital filed a Schedule 13D reporting beneficial ownership of                                                                                                                                                     
 approximately 12,526,486 shares of common stock, representing 9.6% of the Company’s outstanding stock. In its filing, Deep Track Capital stated its intention to engage in discussions with the Company’s management and Board about a variety       
 of topics relating to the Company’s performance, business, operations, strategic opportunities, governance (including Board composition), and optimal use of excess cash, which Deep Track Capital indicated would, in its view, be best deployed by 
 returning capital to shareholders rather than in-licensing of capital intensive development stage drug candidates or unnecessary business combinations or dispositions involving the Company or certain of its                                       
 businesses.                                                                                                                                                                                                                                          |

5

| • |     | On October 24, 2024, Deep Track Capital filed an amendment to its Schedule 13D reporting beneficial                  
 ownership of approximately 17,791,486 shares of common stock, representing 13.6% of the Company’s outstanding stock. |

| • |     | On November 8, 2024, the Company entered into a $100 million accelerated share repurchase plan. |

6

| Company’s counsel indicated that the Board was eager to add that individual as a director (potentially as part of any solution that Deep Track Capital and the Board might arrive at). The 
 Company’s counsel warned that if Deep Track Capital did not share the names of Deep Track Capital’s